Loading…
Serina Therapeutics, Inc. is projected to rise to $2.26 by 2027, a +26% move from its current price of $1.80. SER is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.71 | $1.80 | $1.90 | +0.10% |
| May 30 | $1.67 | $1.80 | $1.94 | +0.21% |
| May 31 | $1.65 | $1.81 | $1.98 | +0.31% |
| Jun 1 | $1.62 | $1.81 | $2.01 | +0.42% |
| Jun 2 | $1.61 | $1.81 | $2.04 | +0.52% |
| Jun 3 | $1.59 | $1.81 | $2.06 | +0.63% |
| Jun 4 | $1.58 | $1.81 | $2.09 | +0.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.58 | $1.81 | $2.09 | +0.74% |
| Week 2 | $1.50 | $1.83 | $2.23 | +1.48% |
| Week 3 | $1.44 | $1.84 | $2.35 | +2.22% |
| Week 4 | $1.40 | $1.85 | $2.46 | +2.97% |
| Week 5 | $1.36 | $1.87 | $2.56 | +3.73% |
| Week 6 | $1.33 | $1.88 | $2.66 | +4.49% |
| Week 7 | $1.31 | $1.89 | $2.75 | +5.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Serina Therapeutics, Inc. is a biotechnology company focused on developing drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc.
was founded in 2006 and is headquartered in Huntsville, Alabama.
Serina Therapeutics, Inc. (SER) is categorized in Healthcare and is currently priced at $1.80 per share with a market capitalization of $27M. It holds the 4793 rank by market cap. The stock trades in a market that is sized at $27M, reflecting a relatively small-cap biotechnology profile.
The 30-day technical picture shows a neutral setup with the stock oscillating around short- and longer-term averages. The year-by-year forecast provides a path of incremental moves through 2050, with notable bullish years and some downside risk in certain years.
A major floor 32.6% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 16.7% above — a clean break opens room to run.
A major ceiling 96.7% above — clearing it would confirm fresh momentum.
Key SER support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SER market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.86 | Sell | $1.83 | Sell |
| MA 10 | $1.73 | Buy | $1.79 | Buy |
| MA 20 | $1.76 | Buy | $1.79 | Buy |
| MA 50 | $1.96 | Sell | $1.91 | Sell |
| MA 100 | $2.07 | Sell | $2.25 | Sell |
| MA 200 | $3.26 | Sell | $3.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.44 | Neutral |
| Stoch RSI (14) | 64.26 | Neutral |
| CCI (20) | 27.31 | Neutral |
| Williams %R (14) | -38.30 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 2.86 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 61.70 | Neutral |
| TRIX (15) | -0.52 | Sell |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 54.90 | Neutral |
| Momentum (10) | 0.17 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.98 | Sell |
| ADX (14) | 12.23 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50. The stock’s short-term momentum sits around the middle of a typical range, not signaling overbought or oversold conditions. The SMA50 is $1.96 and the SMA200 is $3.26, illustrating a mixed view between near-term support and longer-term resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.28 | $1.80 | $2.96 | 0% | Neutral | |
| $1.63 | $2.26 | $3.40 | +26% | Bullish | |
| $1.45 | $2.14 | $3.42 | +19% | Neutral | |
| $1.27 | $1.97 | $3.31 | +10% | Neutral | |
| $1.06 | $1.73 | $3.01 | -4% | Neutral | |
| $1.19 | $2.01 | $3.63 | +12% | Neutral | |
| $1.30 | $2.30 | $4.27 | +28% | Bullish | |
| $1.37 | $2.53 | $4.83 | +41% | Bullish | |
| $1.55 | $2.96 | $5.79 | +65% | Bullish | |
| $1.28 | $2.54 | $5.08 | +41% | Bullish | |
| $1.72 | $3.82 | $8.39 | +112% | Bullish | |
| $2.19 | $4.87 | $11.21 | +171% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.28 | $1.80 | $2.13 | +0.00% |
| June 2026 | $1.54 | $1.85 | $2.29 | +2.58% |
| July 2026 | $1.62 | $1.98 | $2.52 | +7.24% |
| August 2026 | $1.59 | $1.96 | $2.55 | -0.98% |
| September 2026 | $1.54 | $1.93 | $2.54 | -1.68% |
| October 2026 | $1.65 | $2.08 | $2.78 | +7.84% |
| November 2026 | $1.73 | $2.20 | $2.98 | +5.96% |
| December 2026 | $1.69 | $2.16 | $2.96 | -1.73% |
Click any year to see its month-by-month SER forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SER is projected to trade between $1.28 and $2.96, averaging $1.80 — a potential gain of 0% from today's $1.80. A consolidation phase looks the most probable path here.
Serina Therapeutics, Inc.'s 2027 outlook centres on $2.26, within a $1.63 to $3.40 range. That is up +26% on the projected 2026 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2028, SER could reach as high as $3.42, with a base case around $2.14 and support toward $1.45 — roughly +19% from $1.80. A consolidation phase looks the most probable path here.
Expect SER to range from $1.27 to $3.31 through 2029. The $1.97 average target implies a +10% move from current prices. That is -8% versus the projected 2028 average. Price action looks broadly range-bound.
The SER price prediction for 2030 points to an average of $1.73 (low $1.06, high $3.01) — a potential decline of -4% on today's $1.80. A consolidation phase looks the most probable path here.
In 2031, SER is projected to trade between $1.19 and $3.63, averaging $2.01 — a potential gain of +12% from today's $1.80. That is up +16% on the projected 2030 average. Price action looks broadly range-bound.
Serina Therapeutics, Inc.'s 2032 outlook centres on $2.30, within a $1.30 to $4.27 range. That is up +14% on the projected 2031 average. That marks a +28% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SER could reach as high as $4.83, with a base case around $2.53 and support toward $1.37 — roughly +41% from $1.80. Momentum favours further upside here.
Expect SER to range from $1.55 to $5.79 through 2034. The $2.96 average target implies a +65% move from current prices. That is up +17% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SER price prediction for 2035 points to an average of $2.54 (low $1.28, high $5.08) — a potential gain of +41% on today's $1.80. Momentum favours further upside here.
In 2040, SER is projected to trade between $1.72 and $8.39, averaging $3.82 — a potential gain of +112% from today's $1.80. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Serina Therapeutics, Inc.'s 2050 outlook centres on $4.87, within a $2.19 to $11.21 range. That is up +28% on the projected 2040 average. That marks a +171% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SER today (≈ 555.555556 SER) could be worth
$2,707.66
+$1,707.66 (+171%) by 2050 · US Dollar
Based on the average projected SER price of $4.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SERwould be worth at today's price.
$1,000 invested in SER on May 27, 2025 (≈ 169.491523 SER) would be worth
$305.08
-$694.92 (-69.5%) today · 0.31× · US Dollar
Based on a SER entry price of $5.9 vs. today's $1.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.7 | $1,058.82 | +5.9% |
| 1 month ago | $1.8 | $1,000 | +0.0% |
| 3 months ago | $1.81 | $994.48 | -0.6% |
| 6 months ago | $4.26 | $422.54 | -57.7% |
| 1 year ago | $5.9 | $305.08 | -69.5% |
| All time (5.0y) ago | $45.36 | $39.69 | -96.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SER forecast.
Our base-case forecast reaches $3.60 around 2040.
Implied market cap at $3.60: $53.99M
In 2026, the forecast shows a min of $1.28, an avg of $1.80, and a max of $2.96, with ROI 0 and sentiment NEUTRAL. The 2027 outlook improves to a min of $1.63, avg $2.26, max $3.40, ROI 25.6, sentiment BULLISH. The 2028 and 2029 pictures remain mixed with 2028 at min $1.45, avg $2.14, max $3.42 (ROI 19) and 2029 at min $1.27, avg $1.97, max $3.31 (ROI 9.7).
The 2030 forecast softens to min $1.06, avg $1.73, max $3.01 (ROI -3.9). The 2032-2035 window turns more bullish: 2032 avg $2.30 (ROI 27.8), 2033 avg $2.53 (ROI 40.5), 2034 avg $2.96 (ROI 64.6), and 2035 avg $2.54 (ROI 41.1). The long-range view shows strong upside, with 2040 avg $3.82 (ROI 112.2) and 2050 avg $4.87 (ROI 170.8), driven by bullish sentiment in these later years.
These figures emphasize that, while some years show modest or negative returns, the longer horizon contains pronounced upside potential with higher max prices in the 2030s through 2050.
Tap a question to reveal the answer.
The 2030 forecast lists min $1.06, avg $1.73, max $3.01 with ROI -3.9 and sentiment NEUTRAL.
The forecast shows a mix of years, with 2027 and the 2032-2035 period labeled BULLISH and positive ROI in those years, but 2030 shows a negative ROI. Overall, these are estimates with both upside and risk.
Yes. The 2034 forecast lists a max of $5.79, which would exceed $5.
The 2032 forecast shows min $1.30, avg $2.30, max $4.27 with ROI 27.8 and sentiment BULLISH.
For 2040, the forecast is min $1.72, avg $3.82, max $8.39 with ROI 112.2 and sentiment BULLISH. For 2050, the forecast is min $2.19, avg $4.87, max $11.21 with ROI 170.8 and sentiment BULLISH.
Serina Therapeutics, Inc. Community Discussion
0Share your Serina Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.